S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory and Locally Advanced Breast Cancer
Sponsor: National Cancer Institute (NCI)
Listed as NCT00016406, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — May 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aberdeen, United States, Adrian, United States, Albuquerque, United States, Allentown, United States, Alton, United States, Amarillo, United States, American Fork, United States, Anchorage, United States, Anderson, United States, Asheville, United States and 194 more location s